Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors

DOI: 10.1080/2162402X.2016.1168557

Keywords: Affinity, bispecific, disialoganglioside GD2, immunotherapy, scFv, stability

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text